Bay Harbor Wealth Management LLC Has $105,000 Stake in Boston Scientific Corporation $BSX

Bay Harbor Wealth Management LLC reduced its position in Boston Scientific Corporation (NYSE:BSX) by 13.7% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 973 shares of the medical equipment provider’s stock after selling 155 shares during the period. Bay Harbor Wealth Management LLC’s holdings in Boston Scientific were worth $105,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in BSX. Vanguard Group Inc. increased its stake in shares of Boston Scientific by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock valued at $13,577,311,000 after buying an additional 1,697,945 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Boston Scientific by 18.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider’s stock valued at $1,070,387,000 after buying an additional 1,664,108 shares during the period. Assenagon Asset Management S.A. increased its stake in shares of Boston Scientific by 161.9% in the 1st quarter. Assenagon Asset Management S.A. now owns 2,485,696 shares of the medical equipment provider’s stock valued at $250,757,000 after buying an additional 1,536,663 shares during the period. Swedbank AB increased its stake in shares of Boston Scientific by 114.5% in the 2nd quarter. Swedbank AB now owns 2,819,249 shares of the medical equipment provider’s stock valued at $302,816,000 after buying an additional 1,505,019 shares during the period. Finally, Goldman Sachs Group Inc. increased its stake in shares of Boston Scientific by 10.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock valued at $1,426,779,000 after buying an additional 1,383,524 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Jefferies Financial Group restated a “hold” rating on shares of Boston Scientific in a research report on Monday, July 21st. Leerink Partnrs upgraded Boston Scientific to a “strong-buy” rating in a research report on Monday, June 16th. Barclays raised their price target on Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a research report on Thursday. Canaccord Genuity Group raised their price target on Boston Scientific from $131.00 to $132.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Truist Financial raised their price target on Boston Scientific from $125.00 to $129.00 and gave the stock a “buy” rating in a research report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $120.79.

Insiders Place Their Bets

In other Boston Scientific news, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the transaction, the director directly owned 18,479 shares in the company, valued at approximately $1,959,328.37. The trade was a 17.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Yoshiaki Fujimori sold 2,901 shares of the business’s stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the sale, the director owned 2,081 shares in the company, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 174,214 shares of company stock valued at $17,972,457. Insiders own 0.50% of the company’s stock.

Boston Scientific Stock Performance

BSX stock opened at $97.30 on Friday. The business’s 50-day moving average price is $102.93 and its two-hundred day moving average price is $102.06. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The firm has a market cap of $144.17 billion, a PE ratio of 57.91, a P/E/G ratio of 2.34 and a beta of 0.61. Boston Scientific Corporation has a 1-year low of $80.64 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company’s revenue for the quarter was up 22.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, research analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.